Q-omics provides the consensus-scored ZNF281 profile across patient tissues and cancer cell-line models. ZNF281 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZNF281 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ZNF281 RNA expression shows 20,552 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where ZNF281 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF281 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF281 survival associations across molecular data types. ZNF281 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF281 RNA expression–survival associations across cancer types. High ZNF281 expression shows unfavorable associations in KIRP, MESO, UVM, CESC and LUSC, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZNF281 RNA expression.
This table summarizes ZNF281 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF281. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF281 shows higher tumor expression in HNSC, LUAD, KIRC, STAD, BLCA and READ. The HNSC box plot shows higher ZNF281 RNA expression in tumor versus normal tissue (log2 FC = +2.005, t-test p < 0.001).
This table shows molecular features associated with ZNF281 in patient tissues and cancer cell lines. In patient samples, ZNF281 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF281 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
